Abstract
Intercellular communication through gap junctions is essential for the regulation of normal cellular processes. In the diseased state, however, gap junctions may be decreased, inappropriately expressed, or constitutively expressed in either the open or closed state. Thus, it may prove important to develop therapeutic agents to either induce or prevent channel closure. To address this dilemma, the mechanisms that cause channel gating as well as the structure-function and permeability determinants of connexins provide useful information. Residues in the C-terminal tail of Connexin 43 are implicated as sites for phosphorylation by kinases that directly mediate channel gating as well as binding sites that influence gating properties. Gating of gap junctions by pH, insulin, and other growth factors has also been associated with the C-terminal domain. The rational design of inhibitors to channel gating may prove useful for the development of therapeutic agents to maintain Connexin 43 in the open state, with potential benefits in diseases such as cancer, arrhythmias, and the diabetic lens. Alternatively, modeling approaches to obtain gap junctions that are constitutively closed might be targeted to designing compounds that could potentially occlude the pore. In this case, knowledge of the pore-lining residues, as well as permeability determinants, would be useful for developing connexin-specific inhibitors that may have future therapeutic potential for tumor invasiveness and stroke treatment. Thus, information from existing and future studies may lead to the development of site-directed, specific modulators of gap junction communication with potential implications in the therapeutic treatment of disease.
Current Drug Targets
Title: Mutagenic Approaches to Modifying Gap Junction Phenotype
Volume: 3 Issue: 6
Author(s): S. N. Zucker and B. J. Nicholson
Affiliation:
Abstract: Intercellular communication through gap junctions is essential for the regulation of normal cellular processes. In the diseased state, however, gap junctions may be decreased, inappropriately expressed, or constitutively expressed in either the open or closed state. Thus, it may prove important to develop therapeutic agents to either induce or prevent channel closure. To address this dilemma, the mechanisms that cause channel gating as well as the structure-function and permeability determinants of connexins provide useful information. Residues in the C-terminal tail of Connexin 43 are implicated as sites for phosphorylation by kinases that directly mediate channel gating as well as binding sites that influence gating properties. Gating of gap junctions by pH, insulin, and other growth factors has also been associated with the C-terminal domain. The rational design of inhibitors to channel gating may prove useful for the development of therapeutic agents to maintain Connexin 43 in the open state, with potential benefits in diseases such as cancer, arrhythmias, and the diabetic lens. Alternatively, modeling approaches to obtain gap junctions that are constitutively closed might be targeted to designing compounds that could potentially occlude the pore. In this case, knowledge of the pore-lining residues, as well as permeability determinants, would be useful for developing connexin-specific inhibitors that may have future therapeutic potential for tumor invasiveness and stroke treatment. Thus, information from existing and future studies may lead to the development of site-directed, specific modulators of gap junction communication with potential implications in the therapeutic treatment of disease.
Export Options
About this article
Cite this article as:
S. N. Zucker and B. J. Nicholson , Mutagenic Approaches to Modifying Gap Junction Phenotype, Current Drug Targets 2002; 3 (6) . https://dx.doi.org/10.2174/1389450023347218
DOI https://dx.doi.org/10.2174/1389450023347218 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Polymorphisms in Relation to Immunosuppressive Drug Pharmacokinetics in Organ Transplantation: Current Knowledge and Perspectives
Current Pharmacogenomics and Personalized Medicine Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases]
Current Vascular Pharmacology Exploring AT2R and its Polymorphism in Different Diseases: An Approach to Develop AT2R as a Drug Target beyond Hypertension
Current Drug Targets Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Mechanical Circulatory Support of the Critically Ill Child Awaiting Heart Transplantation
Current Cardiology Reviews Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors
Current Medicinal Chemistry Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism Epigenetic Mechanisms in Alzheimer's Disease
Current Medicinal Chemistry Ozone: A Multifaceted Molecule with Unexpected Therapeutic Activity
Current Medicinal Chemistry Magnesium and Anaesthesia
Current Drug Targets Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Does Ceruloplasmin Defend Against Neurodegenerative Diseases?
Current Neuropharmacology Mechanisms of the Beneficial Actions of Ischemic Preconditioning on Subcellular Remodeling in Ischemic-Reperfused Heart
Current Cardiology Reviews Itraconazole Induced Congestive Heart Failure, A Case Study
Current Drug Safety Effect of Dietary Education on Cardiovascular Risk Factors in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Patent Annotations
Recent Patents on Anti-Infective Drug Discovery